Inhibition of apoptosis by downregulation of hBex1, a novel mechanism, contributes to the chemoresistance of Bcr/Abl+ leukemic cells

Carcinogenesis

Volumn 30, Issue 1, 2009, Pages 35-42

  Ding, Kefeng ^a   Su, Yanyan ^a   Pang, Lingrong ^a   Lu, Qinghua ^a   Wang, Zhanhuai ^a   Zhang, Suzhan ^a   Zheng, Shu ^a   Mao, Jianshan ^a   Zhu, Yongliang ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; BCR ABL PROTEIN; BRAIN EXPRESSED X LINKED 1; CADHERIN; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BCL 2; PROTOCADHERIN 10; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DOWNSTREAM PROCESSING; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOLECULAR DYNAMICS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM;

APOPTOSIS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE SILENCING; GENES, ABL; HUMANS; LEUKEMIA; NERVE TISSUE PROTEINS; RNA, SMALL INTERFERING;

EID: 58949085535     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn251     Document Type: Article

References (36)

1. Calabretta,B. et al. (1998) The biology of CML blast crisis. Blood, 103, 4010-4022.
2. Reuther,J.Y. et al. (1998) A requirement for NF-κB activation in Bcr-Abl-mediated transformation. Genes Dev., 12, 968-981.
3. Bedi,A. et al. (1995) BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood, 86, 1148-1158.
4. Skorski,T. et al. (1995) Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosomepositive cells. Blood, 86, 726-736.
5. Radujkovic,A. et al. (2005) Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL-inhibition of P-glycoprotein function by 17-AAG. Leukemia, 19, 1198-1206.
6. Branford,S. et al. (2002) High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood, 99, 3472-3475.
7. Chu,Z.L. et al. (1997) Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Proc. Natl Acad. Sci. USA, 94, 10057-10062.
8. Van Oosterom,A.T. et al. (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet, 358, 1421-1423.
9. Bümming,P. et al. (2003) Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: A centre-based study of 17 patients. Br. J. Cancer, 89, 460-464.
10. Barnes,D.J. et al. (2006) Primitive, quiescent and difficult to kill: The role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle, 5, 2862-2866.
11. Gorre,M.E. et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293, 876-880.
12. Von Bubnoff,N. et al. (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study. Lancet, 359, 487-491.
13. Shah,N.P. et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2, 117-125.
14. Liu,G. et al. (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer, 5, 67.
15. Ma,X. et al. (2005) Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides. Oncol. Rep. 14, 275-279.
16. Dai,Y. et al. (2004) A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J. Biol. Chem., 279, 34227-34239.
17. Kuribara,R. et al. (2004) Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol. Cell. Biol., 24, 6172-6183.
18. Ohmine,K. et al. (2003) Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR. Stem Cells, 21, 315-321.
19. Su,C. et al. (2004) BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood, 103, 3167-3174.
20. Bauer,S. et al. (2006) Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res., 66, 9153-9161.
21. Ferrao,P.T. et al. (2003) Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. Blood, 102, 4499-4503.
22. Mahon,F.X. et al. (2003) MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101, 2368-2373.
23. Zhu,Y. et al. (2005) Transformed immortalized gastric epithelial cells by virulence factor CagA of Helicobacter pylori through Erk mitogen-activated protein kinase pathway. Oncogene, 24, 3886-3895.
24. Kuroda,J. et al. (2006) Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc. Natl Acad. Sci. USA, 103, 14907-14912.
25. Alvarez,E. et al. (2005) Characterization of the Bex gene family in humans, mice, and rats. Gene, 357, 18-28.
26. Chien,J. et al. (2005) Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene, 24, 5089-5100.
27. Mukai,J. et al. (2002) Structure-function analysis of NADE identification of regions that mediate nerve growth factor-induced apoptosis. J. Biol. Chem., 277, 13973-13982.
28. Fischer,C. et al. (2007) Epigenetic regulation of brain expressed X-linked-2, a marker for acute myeloid leukemia with mixed lineage leukemia rearrangements. Leukemia, 21, 374-377.
29. Quentmeier,H. et al. (2005) Expression of BEX1 in acute myeloid leukemia with MLL rearrangements. Leukemia, 19, 1488-1489.
30. Foltz,G. et al. (2006) Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. Cancer Res., 66, 6665-6674.
31. Vilar,M. et al. (2006) Bex1, a novel interactor of the p75 neurotrophin receptor, links neurotrophin signaling to the cell cycle. EMBO J., 25, 1219-1230.
32. Mukai,J. et al. (2000) NADE, a p75NTR-associated cell death executor, is involved in signal transduction mediated by the common neurotrophin receptor p75NTR. J. Biol. Chem., 275, 17566-17570.
33. Becker,E.B. et al. (2004) Characterization of the c-Jun N-terminal kinase-BimEL signaling pathway in neuronal apoptosis. J. Neurosci. 24, 8762-8770.
34. Halbleib,J.M. et al. (2006) Cadherins in develpoment: Cell adhesion, sorting, and tissue morphogenesis. Genes Dev., 20, 3199-3214.
35. Ying,J. et al. (2006) Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene, 25, 1070-1080.
36. Uemura,M. et al. (2007) OL-Protocadherin is essential for growth of striatal axons and thalamocortical projections. Nat. Neurosci., 10, 1151-1159.